FOLR1 and ovarian carcinoma: Next, FOLR1-specific binder sequences were transferred into second generation CAR constructs, and a functional in vitro high-throughput screening was performed, employing the FOLR1-proficient ovarian cancer cell line OV-90 as well as a CRISPR/Cas9-mediated FOLR1-deficient ovarian cancer cell line OV-90 FOLR1 KO [36].